Sandoz stock gains ophthalmology growth option with Ranluspec launch
Published on 11/13/2026 at 11:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSRanluspec expands European portfolio
- Sandoz launched the ranibizumab biosimilar Ranluspec across the European Union except Germany.
- The product targets several retinal diseases, including wet age-related macular degeneration and diabetic macular oedema.
- The launch supports Sandoz's Bio100 ambition and broadens its ophthalmology portfolio.
Sandoz announced on Thursday, November 12, the European launch of Ranluspec, a ranibizumab biosimilar for patients with retinal diseases. The company said the product was approved by the European Commission in February 2026 with equivalent efficacy and comparable safety to Lucentis, its reference medicine. The announcement was published in Sandoz's media release.
New access to retinal treatment
Ranluspec is being commercialised by Sandoz under a partnership with Lupin, which developed, manufactures and registered the medicine. The launch covers the European Union except Germany, while Sandoz holds semi-exclusive rights in France. In Germany, Sandoz markets another ranibizumab product, Epruvy, under a separate agreement.
The medicine is indicated for several retinal conditions, including neovascular, or wet, age-related macular degeneration, diabetic macular oedema, proliferative diabetic retinopathy, macular oedema following retinal vein occlusion and choroidal neovascularisation. Ranibizumab is designed to inhibit vascular endothelial growth factor A, a protein involved in abnormal blood-vessel growth.
Portfolio step supports Bio100 goal
Sandoz described the launch as an early step toward its Bio100 ambition of building a portfolio of more than 100 biosimilars by 2040. The product also strengthens the company's ophthalmology offering, which already includes Afqlir in Europe and Cimerli in the United States.
Christophe Delenta, Sandoz's President Europe, said the launch should give more patients access to an affordable version of the treatment while supporting the long-term sustainability of European healthcare systems. The statement does not provide a launch price or a financial contribution forecast for Ranluspec.
Stock context for investors
Sandoz stock traded at 93.10 euros on Lang & Schwarz at 11:05 CET on Friday, November 13.
Sandoz stock at a glance
- Company: Sandoz Group AG
- ISIN: CH1243598427
- Listing ticker: SDZ
- Latest quote: 93.10 euros on Lang & Schwarz, Friday, November 13, 2026, at 11:05 CET
In the broader Swiss market, investors can follow developments through the SMI market overview.
For more developments, visit More news and analyses on Sandoz stock.
